vs
Embecta Corp.（EMBC）とRevolve Group, Inc.（RVLV）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revolve Group, Inc.の直近四半期売上が大きい（$324.4M vs $261.2M、Embecta Corp.の約1.2倍）。Embecta Corp.の純利益率が高く（16.9% vs 5.7%、差は11.2%）。Revolve Group, Inc.の前年同期比売上増加率が高い（10.4% vs -0.3%）。Embecta Corp.の直近四半期フリーキャッシュフローが多い（$16.6M vs $-13.3M）。過去8四半期でRevolve Group, Inc.の売上複合成長率が高い（9.5% vs -4.6%）
Embecta Corp.は糖尿病ケアソリューションを専門とするグローバル医療テクノロジー企業です。インスリンペンニードル、注射器、輸液セット部品などを開発・製造・販売し、北米、欧州、アジア太平洋地域の患者、医療従事者、製薬企業にサービスを提供しています。
Revolve Theatre Companyはテムズ河畔ヘンリーを拠点とする劇団で、政治的なテーマの作品やシェイクスピア劇を専門に制作・上演しており、オリバー・デンチ、ジョー・モリス、トム・スミスの3人が所有しています。
EMBC vs RVLV — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $261.2M | $324.4M |
| 純利益 | $44.1M | $18.6M |
| 粗利率 | 61.9% | 53.3% |
| 営業利益率 | 31.9% | 6.3% |
| 純利益率 | 16.9% | 5.7% |
| 売上前年比 | -0.3% | 10.4% |
| 純利益前年比 | — | 50.4% |
| EPS（希薄化後） | $0.74 | $0.27 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $261.2M | $324.4M | ||
| Q3 25 | $264.0M | $295.6M | ||
| Q2 25 | $295.5M | $309.0M | ||
| Q1 25 | $259.0M | $296.7M | ||
| Q4 24 | $261.9M | $293.7M | ||
| Q3 24 | $286.1M | $283.1M | ||
| Q2 24 | $272.5M | $282.5M | ||
| Q1 24 | $287.2M | $270.6M |
| Q4 25 | $44.1M | $18.6M | ||
| Q3 25 | $26.4M | $21.2M | ||
| Q2 25 | $45.5M | $10.2M | ||
| Q1 25 | $23.5M | $11.8M | ||
| Q4 24 | $0 | $12.3M | ||
| Q3 24 | $14.6M | $11.0M | ||
| Q2 24 | $14.7M | $15.4M | ||
| Q1 24 | $28.9M | $10.9M |
| Q4 25 | 61.9% | 53.3% | ||
| Q3 25 | 60.0% | 54.6% | ||
| Q2 25 | 66.7% | 54.1% | ||
| Q1 25 | 63.4% | 52.0% | ||
| Q4 24 | 60.0% | 52.5% | ||
| Q3 24 | 60.7% | 51.2% | ||
| Q2 24 | 69.8% | 54.0% | ||
| Q1 24 | 64.6% | 52.3% |
| Q4 25 | 31.9% | 6.3% | ||
| Q3 25 | 21.4% | 7.1% | ||
| Q2 25 | 31.8% | 5.8% | ||
| Q1 25 | 24.3% | 5.0% | ||
| Q4 24 | 11.0% | 3.9% | ||
| Q3 24 | 9.2% | 5.0% | ||
| Q2 24 | 20.5% | 5.8% | ||
| Q1 24 | 13.6% | 3.4% |
| Q4 25 | 16.9% | 5.7% | ||
| Q3 25 | 10.0% | 7.2% | ||
| Q2 25 | 15.4% | 3.3% | ||
| Q1 25 | 9.1% | 4.0% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | 5.1% | 3.9% | ||
| Q2 24 | 5.4% | 5.4% | ||
| Q1 24 | 10.1% | 4.0% |
| Q4 25 | $0.74 | $0.27 | ||
| Q3 25 | $0.44 | $0.29 | ||
| Q2 25 | $0.78 | $0.14 | ||
| Q1 25 | $0.40 | $0.16 | ||
| Q4 24 | $0.00 | $0.18 | ||
| Q3 24 | $0.24 | $0.15 | ||
| Q2 24 | $0.25 | $0.21 | ||
| Q1 24 | $0.50 | $0.15 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $201.3M | $292.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $-613.1M | $512.5M |
| 総資産 | $1.1B | $765.0M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $201.3M | $292.3M | ||
| Q3 25 | $225.5M | $315.4M | ||
| Q2 25 | $230.6M | $310.7M | ||
| Q1 25 | $209.3M | $300.8M | ||
| Q4 24 | $210.0M | $256.6M | ||
| Q3 24 | $267.5M | $252.8M | ||
| Q2 24 | $275.1M | $244.7M | ||
| Q1 24 | $299.8M | $273.4M |
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-613.1M | $512.5M | ||
| Q3 25 | $-650.6M | $490.2M | ||
| Q2 25 | $-669.6M | $468.6M | ||
| Q1 25 | $-736.2M | $453.4M | ||
| Q4 24 | $-768.8M | $437.8M | ||
| Q3 24 | $-738.3M | $420.8M | ||
| Q2 24 | $-763.7M | $405.8M | ||
| Q1 24 | $-769.6M | $389.9M |
| Q4 25 | $1.1B | $765.0M | ||
| Q3 25 | $1.1B | $751.3M | ||
| Q2 25 | $1.2B | $722.9M | ||
| Q1 25 | $1.1B | $713.9M | ||
| Q4 24 | $1.1B | $665.5M | ||
| Q3 24 | $1.3B | $670.9M | ||
| Q2 24 | $1.3B | $657.8M | ||
| Q1 24 | $1.2B | $650.0M |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $17.2M | $-10.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $16.6M | $-13.3M |
| FCFマージンFCF / 売上 | 6.4% | -4.1% |
| 設備投資強度設備投資 / 売上 | 0.2% | 1.0% |
| キャッシュ転換率営業CF / 純利益 | 0.39× | -0.55× |
| 直近12ヶ月FCF直近4四半期 | $205.8M | $48.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $17.2M | $-10.2M | ||
| Q3 25 | $84.0M | $11.8M | ||
| Q2 25 | $81.2M | $12.6M | ||
| Q1 25 | $31.8M | $45.1M | ||
| Q4 24 | $-5.3M | $3.9M | ||
| Q3 24 | $26.6M | $9.1M | ||
| Q2 24 | $-2.1M | $-24.7M | ||
| Q1 24 | $24.3M | $38.4M |
| Q4 25 | $16.6M | $-13.3M | ||
| Q3 25 | $76.7M | $7.5M | ||
| Q2 25 | $80.8M | $10.4M | ||
| Q1 25 | $31.7M | $43.4M | ||
| Q4 24 | $-6.8M | $2.1M | ||
| Q3 24 | — | $8.0M | ||
| Q2 24 | $-11.8M | $-25.7M | ||
| Q1 24 | $20.9M | $36.7M |
| Q4 25 | 6.4% | -4.1% | ||
| Q3 25 | 29.1% | 2.5% | ||
| Q2 25 | 27.3% | 3.4% | ||
| Q1 25 | 12.2% | 14.6% | ||
| Q4 24 | -2.6% | 0.7% | ||
| Q3 24 | — | 2.8% | ||
| Q2 24 | -4.3% | -9.1% | ||
| Q1 24 | 7.3% | 13.5% |
| Q4 25 | 0.2% | 1.0% | ||
| Q3 25 | 2.8% | 1.5% | ||
| Q2 25 | 0.1% | 0.7% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.6% | 0.6% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 3.6% | 0.4% | ||
| Q1 24 | 1.2% | 0.6% |
| Q4 25 | 0.39× | -0.55× | ||
| Q3 25 | 3.18× | 0.56× | ||
| Q2 25 | 1.78× | 1.24× | ||
| Q1 25 | 1.35× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | 1.82× | 0.83× | ||
| Q2 24 | -0.14× | -1.60× | ||
| Q1 24 | 0.84× | 3.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
